First in human (FIH) clinical trials of bispecific immunostimulatory antibodies commonly require a low starting dose based on a minimum anticipated biological effect level (MABEL) approach. To ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback